U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C25H28N6O.2ClH.3H2O
Molecular Weight 984.027
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRBESARTAN HYDROCHLORIDE SESQUIHYDRATE

SMILES

O.O.O.Cl.Cl.CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5.CCCCC6=NC7(CCCC7)C(=O)N6CC8=CC=C(C=C8)C9=CC=CC=C9C%10=NN=NN%10

InChI

InChIKey=WCTHVUNSKZGLLG-UHFFFAOYSA-N
InChI=1S/2C25H28N6O.2ClH.3H2O/c2*1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23;;;;;/h2*4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30);2*1H;3*1H2

HIDE SMILES / InChI

Description

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.

Originator

Approval Year

1997
189
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 1.1 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

1997
Primary
Approved
8583
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.9 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.9 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.3 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.04 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.3 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.6 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
9.7 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.6 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.8 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.3 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
19.8 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
31.9 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34.2 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9549663
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020758s079lbl.pdf
unknown, unknown
 IRBESARTAN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9549663
healthy, 20-45
Health Status: healthy
Age Group: 20-45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9549663
Sources:
https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
Disc. AE: Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (2.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Disorder fetal Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
Hyperkalemia 2.1%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
substrate
1193

inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
132

CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2E1
1060

Kv4.3
16

P-gp
1741

BCRP
910

MRP2
499
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 no [IC50 224 uM]
CYP1A2
2333
 no [IC50 483 uM]
CYP2A6
911
 no [IC50 >1000 uM]
CYP2D6
2546
 no [IC50 >1000 uM]
CYP2E1
1146
 no [IC50 >1000 uM]
BCRP
985
 no
CYP1A1
272
 no
CYP2B6
1160
 no
MRP2
625
 no
P-gp
1932
 weak
CYP2C9
2497
 yes [IC50 172 uM]
Kv4.3
16
 yes [IC50 7.2 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 yes
CYP2C9
1193
 yes
yes (co-administration study)
Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible
Page: 12.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5959
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5959
ChemicalBook
CB4454663
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4454663
eMolecules
32278040
https://www.emolecules.com/cgi-bin/more?vid=32278040
eMolecules
901986
https://www.emolecules.com/cgi-bin/more?vid=901986
MolPort
MolPort-003-666-550
https://www.molport.com/shop/molecule-link/MolPort-003-666-550
MolPort
MolPort-006-167-687
https://www.molport.com/shop/molecule-link/MolPort-006-167-687
Selleck Chemicals
Irbesartan(Avapro)
http://www.selleckchem.com/products/Irbesartan(Avapro).html
ZINC
ZINC000003872931
http://zinc15.docking.org/substances/ZINC000003872931
PubMed

PubMed

TitleDatePubMed
Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
2002-01-05
Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
2002-01-05
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.
2002-01
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.
2002-01
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
2001-12
AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.
2001-12
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
2001-11-15
Drug companies should not have the final say in the design of clinical trials.
2001-11
Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
2001-11
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
2001-10-15
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
2001-10-09
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
2001-10-06
[Irbesartan in hypertension. A plus for therapy compliance].
2001-10-04
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
2001-10-01
[Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].
2001-10
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
2001-10
Relation between clinical and therapeutic variables and quality of life in hypertension.
2001-10
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
2001-10
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
2001-10
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
2001-10
A clinical trial in type 2 diabetic nephropathy.
2001-10
Angiotensin II receptor blockers and nephropathy trials.
2001-10
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
2001-10
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
2001-09-20
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
2001-09-20
Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat.
2001-09-01
Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.
2001-09
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.
2001-09
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
2001-09
Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors.
2001-09
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
2001-09
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
2001-09
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
2001-09
[Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency].
2001-08-25
New stuff about the diabetic kidney.
2001-08-11
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
2001-08-09
Acute oliguric renal failure associated with angiotensin II receptor antagonists.
2001-08
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
2001-08
Irbesartan achieves consistent and effective use over 1 year.
2001-07-28
[Angiotensin II receptor antagonists: different or equivalent?].
2001-07-27
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
2001-07
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
2001-04
Pharmacology of AT1-receptor blockers.
2001
The relationship between dose and antihypertensive effect for different AT1-receptor blockers.
2001
Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.
2001
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
2001
Drug interactions with irbesartan.
2001
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].
2001
Hypertension and diabetes: the scope of the problem.
2001
Clinical differences among angiotensin II receptor antagonists.
2001
Patents

Patents

JP2001089393A
6
JP2005041875A
13
JP2006513266A
25
JP2006515566A
3
JP2010053048A
3
JP2011510003A
50

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Hypertension Initial dose: 150 mg orally once a day Maximum dose: 300 mg orally once a day Usual Adult Dose for Diabetic Nephropathy Target maintenance dose: 300 mg orally once a day Use: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (greater than 300 mg/day) in patients with type 2 diabetes and hypertension.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Contraction responses to increasing concentrations of Ang I (1 nM-1 uM) were evaluated in organ baths in the presence of captopril (10 uM-1 mM) with or without a chymase inhibitor (1 uM soybean trypsin inhibitor), or irbesartan (0.1 nM-uM), in internal mammary arteries from 25 patients undergoing coronary bypass surgery.
0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)
Name Type Language
1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, MONOHYDROCHLORIDE, HYDRATE (2:3)
Preferred Name English
IRBESARTAN HYDROCHLORIDE SESQUIHYDRATE
Common Name English
1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, HYDROCHLORIDE, HYDRATE (2:2:3)
Systematic Name English
Code System Code Type Description
CAS
874657-02-0
Created by admin on Wed Apr 02 11:18:58 GMT 2025 , Edited by admin on Wed Apr 02 11:18:58 GMT 2025
PRIMARY
FDA UNII
B4WCH9U6Q3
Created by admin on Wed Apr 02 11:18:58 GMT 2025 , Edited by admin on Wed Apr 02 11:18:58 GMT 2025
PRIMARY
PUBCHEM
162625107
Created by admin on Wed Apr 02 11:18:58 GMT 2025 , Edited by admin on Wed Apr 02 11:18:58 GMT 2025
PRIMARY
SMS_ID
300000000781
Created by admin on Wed Apr 02 11:18:58 GMT 2025 , Edited by admin on Wed Apr 02 11:18:58 GMT 2025
PRIMARY
PARENT (SALT/SOLVATE)
Structure of Irbesartan
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966